Oncology
|
Strategies for Maintaining Bone Health in Your Oncology Patient: A Case-Based Approach |
|
Go to: Part 1 | Part 2 | Part 3 | Part 4 | Part 5
Part 1: Bone Health Matters:
| |
| Dear Colleague: | |
| Bone is one of the most frequent sites for metastasis. Bone metastases occur in up to 75% of patients with breast cancer, up to 80% of patients with prostate cancer, and up to 34% of patients with non—small-cell lung cancer. In patients newly diagnosed with multiple myeloma, nearly 80% already have lytic lesions, osteoporosis, or fractures. The consequences of bone metastasis and lytic lesions can be devastating–severe bone pain, pathologic fractures, life-threatening hypercalcemia, and nerve compression syndromes, including spinal cord compression. | |
| A large array of growth factors, cytokines and chemokines, produced or induced by tumors in the bone microenvironment, disrupt the normal bone remodeling process, which maintains the balance of resorption and rebuilding. Within the setting of metastases, bone density is lost and new bone growth is of poor quality. An understanding of these bone physiologic processes has led to the successful bisphosphonate standard-of-care treatments we have today. This Tx Reporter will review the physiology of bone remodeling and survey the latest advances in current bisphosphonate therapy, as well as the development of key novel agents. | |
| "Bone Health Matters: Overview of Disease- and Treatment-Related Skeletal Complications," is the first Tx Reporter in a five-part series titled, Strategies for Maintaining Bone Health in Your Oncology Patient: A Case-Based Approach. In these five newsletters and audio CDs, our faculty will present the latest clinical data and expert opinion on managing bone health in patients with lung, breast, and prostate cancer, and mutiple myeloma. | |
| Thank you for participating in this series. We are pleased to assist you in improving the bone health of your oncology patients. | |
| Sincerely, | |
| top |
|
TARGET AUDIENCE |
|
| This CME/CE activity is designed for oncologists, nurses, and pharmacists involved in the treatment of patients with a variety of tumor types and experiencing bone complications/bone loss. | |
ACTIVITY GOAL |
|
| The goal of this CME/CE activity is to examine current and emerging strategies in the treatment of bone metastases and cancer-treatment–induced bone loss in patients with a variety of tumor types. | |
LEARNING OBJECTIVES |
|
|
|
| top | |
CME Information: Physicians |
|
Statement of Accreditation |
|
| Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. | |
Credit Designation |
|
| Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. (You can earn up to 10 credits for completing all 5 parts.) |
|
CE Information: Nurses |
|
| This activity has been approved by the American Association of Critical-Care Nurses (AACN) for 1.5 contact hours. Provider #00012705. (You can earn up to 7.5 credits for completing all 5 parts.) |
|
CE Information: Pharmacists |
|
 Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the program for 2 contact hours (0.2 CEUs) is 052-000-06-022-H01. (You can earn up to 1.0 CEUs [10 contact hours] for completing all 5 parts.) |
|
CME/CE Instructions |
|
|
|
|
|
| top | |
DISCLOSURE INFORMATION |
|
| The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. | |
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR). |
|
Allan Lipton, MD, is on the speakers bureau of and is a consultant for Amgen Inc and Novartis Pharmaceuticals Corporation; and is a consultant for Incyte Corporation, Merck & Co, Inc, and Novartis Pharmaceuticals Corporation. Dr. Lipton has disclosed that he will reference the use of atrasentin, cathepsin K, CGP77675 (Src inhibitor), clodronate, denosumab, pamidronate, and zoledronic acid. |
|
G. David Roodman, MD, PhD, is on the speakers bureau of Celgene Corporation, Millennium Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation; and is a consultant for Amgen Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, and Scios Inc. Dr. Roodman has disclosed that he will not reference unlabeled or unapproved uses of drugs or products in his presentation. |
|
Peer Reviewer has disclosed no significant relationships. |
|
Projects In Knowledge's staff members have no significant relationships to disclose. |
|
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. |
|
This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient. |
|
This independent CME/CE activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. | |
| top
1754.01 |
|
|
|
